Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23983814 | 0.95 | ABCG2 (0.35) | ABCG2TDP1L3MBTL1AHRKDM4E | |
| SCHEMBL23984011 | 0.93 | — | — | |
| SCHEMBL23983738 | 0.93 | TDP1 (0.34) | ABCG2TDP1L3MBTL1KDM4EMEN1 | |
| SCHEMBL26973592 | 0.91 | HCRTR1 (0.32) | AHRHCRTR1 | |
| SCHEMBL23984001 | 0.90 | TDP1 (0.32) | ABCG2TDP1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL23984309 | 0.90 | TDP1 (0.34) | ABCG2TDP1L3MBTL1AHRMEN1 | |
| SCHEMBL26973513 | 0.89 | L3MBTL1 (0.36) | ABCG2TDP1L3MBTL1AHRKDM4E | |
| SCHEMBL23983647 | 0.88 | ABCG2 (0.30) | ABCG2 | |
| SCHEMBL23984026 | 0.88 | TDP1 (0.32) | ABCG2TDP1L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL23983820 | 0.88 | TDP1 (0.31) | TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20210340159-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG CHEM, LTD. (KR) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340159-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | NR4A1, CYP1A1, ARNT | ABCG2 2326/4885TDP1 4237/4885L3MBTL1 402/4885 |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | NR4A1, CYP1A1, ARNT | ABCG2 2326/4885TDP1 4237/4885L3MBTL1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.